DBV Technologies S.A. 10-Q Summary: Q1 2026
Business Context and Reporting Period
This report covers the quarterly period ended March 31, 2026. DBV Technologies S.A. is a late-stage biopharmaceutical company developing Viaskin, an epicutaneous immunotherapy platform. The company is currently focused on the potential U.S. commercialization of Viaskin Peanut for children aged 4 to 7, following positive Phase 3 VITESSE trial results announced in December 2025. The company does not currently generate product revenue and relies on financing and research tax credits.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Operating Income | $0.9 million | $0.8 million |
| Net Loss | $(47.6) million | $(27.1) million |
| Net Loss Per Share (Basic/Diluted) | $(0.11) | $(0.26) |
| Cash and Cash Equivalents (End of Period) | $229.2 million | $13.0 million |
| Net Cash Used in Operating Activities | $(49.1) million | $(19.7) million |
| Net Cash Provided by Financing Activities | $88.9 million | $0 million |
| Total Assets | $266.4 million | N/A (Not provided in text) |
| Total Liabilities | $58.4 million | N/A (Not provided in text) |
Note: The filing text does not provide a clear value for Total Assets or Total Liabilities for Q1 2025.
Material Changes vs. Prior Period
- Operating Expenses: Total operating expenses increased by 78% to $48.8 million from $27.4 million.
- R&D Expenses: Rose 55% to $33.4 million, driven by external clinical costs ($10.0M increase) for the COMFORT Toddlers study and BLA readiness activities.
- Sales & Marketing: Surged 1,750% to $4.8 million from $0.3 million due to the build-out of U.S. commercial infrastructure and the appointment of a Chief Commercial Officer.
- G&A Expenses: Increased 87% to $10.5 million, reflecting expanded legal, HR, and investor relations activities.
- Financing Activity: The company received $88.9 million in net cash from financing activities, primarily from the full exercise of warrants from the March 2025 PIPE financing ($94.7 million received in January 2026).
- Share Count: Weighted average shares outstanding increased significantly to 428.3 million from 102.6 million, diluting the net loss per share impact despite higher absolute losses.
- Currency Impact: A depreciation of the Euro against the U.S. Dollar resulted in a $4.4 million unfavorable foreign currency translation adjustment in comprehensive loss.
Guidance, Outlook, and Risks
- Cash Runway: Management estimates the company is sufficiently funded to operate into the second quarter of 2027 based on current plans. This excludes potential additional expenditures for new programs or acquisitions.
- Strategic Milestones: The company plans to submit a Biologics License Application (BLA) for Viaskin Peanut (ages 4-7) in the first half of 2026. The COMFORT Toddlers study (ages 1-3) is ongoing with enrollment targeting 300-350 subjects.
- Commitments: The company has non-cancellable contractual obligations of $88.9 million with CROs and $49.5 million with CMOs (Contract Manufacturing Organizations) over the next several years.
- Risks: Key risks include the sufficiency of capital resources, the timing of regulatory approvals, the success of clinical trials, and the ability to commercialize Viaskin Peanut. The company notes that if operating cash outflows exceed projections, additional financing may be required earlier than anticipated.
Investor Verification Checklist
- Verify the timeline and requirements for the anticipated BLA submission for Viaskin Peanut in H1 2026.
- Confirm the status of the COMFORT Toddlers study enrollment and the timeline for confirmatory effectiveness studies.
- Review the terms of the Manufacturing Supply Agreements with Fareva La Vallée and Sanofi, specifically regarding minimum purchase obligations.
- Monitor the company's cash burn rate against the projected runway to Q2 2027, considering potential FX volatility.
- Assess the progress of the U.S. commercial infrastructure build-out and associated cost escalations.